Paliperidone induced neutropenia in first episode psychosis: a case report

Natalie Martos†, William Hall†, Alicia Marhefka, Thomas W. Sedlak and Frederick C. Nucifora Jr *

Abstract

Background: Neutropenia, a decrease in total number of neutrophils below 1500/mm³ and particularly severe neutropenia, defined as neutrophils less than 500/mm³, is a potential adverse effect of antipsychotic medications that can lead to increased risk of infections and death. However, much of the attention on the potential adverse effect is centered exclusively on clozapine, which remains the only antipsychotic medication in the United States requiring standardized monitoring of blood work. We demonstrate here that paliperidone can also cause neutropenia and therefore clinicians should be aware of this possibility especially during initiation of treatment.

Case presentation: The following report presents the case of a 23-year-old African American male with first episode psychosis who developed neutropenia after initiation of paliperidone. Neutropenia resolved after discontinuation of paliperidone and initiation of an alternative antipsychotic, haloperidol.

Conclusions: This case report demonstrates an example of paliperidone induced neutropenia which resolved with a switch to haloperidol. We conclude that when initiating paliperidone, clinicians should be more aware of the risk of neutropenia. Moreover, neutropenia may be a more common and overlooked issue in patients on antipsychotic medications other than clozapine and increased awareness of comparative risk across antipsychotics could help direct treatment.

Keywords: First episode psychosis, Neutropenia, Paliperidone, Schizophrenia, Clozapine

Background

Neutropenia, a decrease in total number of neutrophils below 1500/mm³, is a potential adverse effect of antipsychotic medications that can lead to increased risk of infections. However, much of the attention on the potential for neutropenia and severe neutropenia, defined as neutrophils less than 500/mm³, is centered exclusively on clozapine, which remains the only antipsychotic medication in the United States requiring standardized monitoring of blood work [1–3].

In the following case report, we describe a relatively treatment-naïve patient with new onset psychosis whose absolute neutrophil count (ANC) dropped significantly with the initiation of the atypical antipsychotic, paliperidone. We later discuss the future implications of neutropenia in antipsychotic medications other than clozapine.

Case presentation

A 23-year-old African American male with previous high level of social and academic functioning, family history of depression, and no past medical or psychiatric history was admitted to an inpatient psychiatric unit for treatment of several months of uncharacteristic, odd behavior and disorganized thought process. On presentation, the patient could not provide a coherent narrative. His family and friends reported gradual onset of odd behavior within the year prior to admission. These behaviors included wearing his rugby helmet around his college campus, discarding clothes in the trash, and becoming increasingly disheveled in appearance. He drove across...
In our case, neutropenia developed after initiation of paliperidone and resolved within 16 days of discontinuation. Neutrophil levels remained normal after the initiation of haloperidol, indicating that neutropenia was most likely related to the initiation of paliperidone.

We also considered other contributing factors to his neutropenia. He was also treated with clonazepam and escitalopram during his course but with no evidence of temporal relationship to his neutropenia. However, there are reports of clonazepam induced neutropenia [4]. Though clonazepam had been discontinued by the time the patient developed neutropenia, we cannot rule out a possible synergistic effect from both paliperidone and clonazepam. Additionally, while there are no agreed upon risk factors for antipsychotic induced neutropenia (particularly paliperidone-induced), one might reasonably apply risk factors for clozapine induced neutropenia to this case. And in this case, neuroleptic naivety, higher doses of neuroleptics, African American race, male gender, and younger age all may have placed him at greater risk of developing neuroleptic induced neutropenia [5, 6]. Furthermore, we considered the role of benign ethnic neutropenia (BEN); however, hematology consultants did not consider this a factor given his ANC counts being consistently greater than 1500 prior to initiation of neuroleptics.

To date, we are only aware of three other case reports on neutropenia induced by paliperidone. In all three cases, neutropenia resolved within several days to weeks after discontinuation of paliperidone [7–9]. In one case, lithium was successfully added temporarily to counteract the neutropenia [7]. Two of the reports suggested that neutropenia was dose related and concomitant psychiatric medications (divalproex sodium and quetiapine in one case, risperidone in the other) could have also synergistically contributed to development of neutropenia [7, 8]. In all cases, patients had been on their previous regimens without neutropenia prior to initiation of paliperidone. The patient described here highlights that the decrease in ANC may occur at low to middle doses of paliperidone since the Food and Drug Administration FDA maximum dosage is 12 mg and early in the course of treatment. Of note, paliperidone (9-hydroxyrisperidone) is a metabolite of risperidone. A literature review demonstrates evidence of risperidone induced blood dyscrasias, including neutropenia [10, 11]. Thus, it stands to reason that risperidone’s metabolite could also lead to neutropenia.

Our case report highlights the potential for antipsychotics other than clozapine to cause neutropenia. Although clozapine is the antipsychotic most commonly associated with agranulocytosis or severe neutropenia (term now used by the Clozapine Risk Evaluation and Mitigation Strategies program) with an estimated risk of approximately 0.68%, other antipsychotics have also been linked to neutropenia and severe neutropenia including the majority of second generation antipsychotics.
We now present evidence for paliperidone causing neutropenia in a case of first episode psychosis (occurring within the first year of treatment). While there are no guidelines for routine ANC monitoring when using any antipsychotic other than clozapine, our case suggests the potential risk of neutropenia when initiating paliperidone. If we had failed to recognize the precipitous fall in our patient’s neutrophil count, he may have remained on paliperidone indefinitely with increased risk for medication-related morbidity and mortality.

Currently, clozapine is widely recognized as one of the most effective antipsychotic medications available but is underutilized largely due to the barriers to prescribers and heavy burden placed on patients with required regular blood monitoring [2]. After many years of implementation, the utility of long-term clozapine monitoring is still debated. Some evidence suggests that there is not a significant increase in risk for developing neutropenia while on clozapine compared to other medications [12–15] and following the ANC after the first 6 months of treatment may not be as beneficial in preventing fatalities as previously thought [12, 15]. Based on the experiences with clozapine, it would likely be counterproductive to spread this monitoring burden to even more antipsychotics, such as paliperidone, in efforts to mitigate this side effect risk. Further evaluation of how high the risk of neutropenia and severe neutropenia is in the population treated with paliperidone, as well as other newer antipsychotics, would be necessary to fully appreciate the true risk. Ultimately, striking a balance between safely prescribing antipsychotics while still providing effective and accessible treatment will be crucial in the future as newer medications like paliperidone become more widely used. However, this case report highlights the importance of clinicians being aware of the risk and considering obtaining routine ANCs when initiating paliperidone and other antipsychotics.

This case report demonstrates an example of paliperidone-induced neutropenia which resolved with a switch to haloperidol. In general, we conclude that there is sufficient and mounting evidence that most antipsychotics can cause neutropenia and that there may be value in monitoring ANCs early in the course of treatment to ensure stability. However, we would caution against mandatory monitoring with a national registry as this has contributed to the underutilization of clozapine, and thus could disrupt effective utilization of antipsychotics in general. This could also help make the argument to relax mandatory monitoring of clozapine since neutropenia may not be specific to clozapine. The hope is that this case will add to clinicians’ awareness that neutropenia is a risk with neuroleptic treatment, and that it will also spur further studies regarding comparative risk for neutropenia among all neuroleptics and a re-thinking of a mandatory registry for clozapine.

**Abbreviations**

ANC: Absolute Neutrophil Count; ANA: Antinuclear Antibody; HIV: Human Immunodeficiency Virus; FDA: Food and Drug Administration

**Acknowledgements**

None.

**Authors' contributions**

FCN was the primary clinician involved in the assessment, management, and follow-up of the patient. NM, WH, and TW5 were involved in the patient follow-up. FCN conceived the case report. NM, WH, AM, and TW5 contributed to the literature review. All authors contributed to the manuscript preparation. FCN and WH wrote the revisions. All authors read and approved the final manuscript.

**Funding**

No funding sources.

**Availability of data and materials**

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

**Ethics approval and consent to participate**

Written informed consent was obtained from the individual to participate and of any potentially identifiable data included in this article. This study was carried out in accordance with the recommendations of Institutional Review Board of Johns Hopkins University School of Medicine with written informed consent from all subjects.

**Consent for publication**

Written informed consent was obtained from the individual for the publication of this manuscript and of any potentially identifiable data included in this article. This study was carried out in accordance with the recommendations of Institutional Review Board of Johns Hopkins University School of Medicine with written informed consent from all subjects.

**Competing interests**

The authors have no competing interests to declare.

**Received**

21 August 2020 **Accepted**

25 January 2021

**Published online**

06 February 2021

**References**

1. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O’Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483–8. https://doi.org/10.1192/bjp.169.4.483.

2. Nucifora FC Jr, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750–61. https://doi.org/10.1007/s13311-017-0552-9.

3. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998;59(Suppl. 3):3–7.

4. Bautista-Quach MA, Liao YM, Hsieh CT. Pancytopenia associated with clonazepam. J Hematol Oncol. 2010;3:24. https://doi.org/10.1186/1756-8722-3-24.

5. Maher KN, Tan M, Tossell JW, Weisinger B, Gochnich P, Miller R, Greenstein D, Overman GP, Rapoport JL, Gogtay N. Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2013;23(2):101–6. https://doi.org/10.1089/cap.2011.0136.

6. Lally J, Flanagan NJ. Severe neutropenia and agranulocytosis. Life Threatening effects of antipsychotic drugs; 2016. p. 105–48. https://doi.org/10.1016/B978-0-12-803376-0.00005-8. Retrieved from www.sciencedirect.com.

7. Matsura H, Kimoto S, Harada I, Naemura S, Yamamuro K, Kishimoto T. Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder, a case report. BMC Psychiatry. 2016;16:161.
8. Raj V, Drutt T, Purushothaman S, Dunidon J. Risperidone/paliperidone induced neutropenia and lymphopenia. Aust N Z J Psychiatry. 2013;47(3):291–2.

9. Kim JN, Lee BC, Choi IK, Jon DI, Jung NH. Paliperidone-induced leukopenia and neutropenia: a case report. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(1):284–5.

10. Manfredi G, SoFaneli A, Dimitri G, Cuomo I, Sani G, Kotzalidis GD, Girardi P. Risperidone-induced leukopenia: a case report and brief review of literature. Gen Hosp Psychiatry. 2013;35(1):102.e3–6. https://doi.org/10.1016/j.genhosppsych.2012.03.009 ISSN 0163-8343, (http://www.sciencedirect.com/science/article/pii/S0163834312000795).

11. Kattalai Kailasam V, Chima V, Nnamdi U, Sharma K, Shah K. Risperidone-induced reversible neutropenia. Neuropsychiatr Dis Treat. 2017;13:1975–7. https://doi.org/10.2147/NDT.S141472.

12. Schulte P. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006;40(4):683–8.

13. Ingimansson O, Maccabe JH, Haraldsson M, Jónsdóttir H, Sigurdsson E. Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. BMC Psychiatry. 2016;16(1):441.

14. Rettenbacher MA, Hofer A, Kemmler G, Fleischhacker WW. Neutropenia induced by second generation antipsychotics: a prospective investigation. Pharmacopsychiatry. 2010;43(2):41–4.

15. Drew L. Clozapine and agranulocytosis: re-assessing the risks. Australas Psychiatry. 2013;21(4):335–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.